TMDX vs UNH vs INVA vs CVS

For growth investors, TransMedics Group, Inc.

(TMDX) is the stronger pick with 37. 1% revenue growth year-over-year, versus 7. 8% for CVS Health Corporation (CVS). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate TransMedics Group, Inc. (TMDX) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus CVS Health Corporation at 62. 8x. On forward P/E, Innoviva, Inc. is actually cheaper at 11. 9x.

Over the past 5 years, TransMedics Group, Inc.

(TMDX) delivered a total return of +200. 7%, compared to -2. 6% for UnitedHealth Group Incorporated (UNH). Over 10 years, the gap is even starker: TMDX returned +226. 0% versus CVS's +3. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.

05β versus TransMedics Group, Inc. 's 1. 59β — meaning TMDX is approximately 3035% more volatile than CVS relative to the S&P 500. On balance sheet safety, Innoviva, Inc. (INVA) carries a lower debt/equity ratio of 23% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TransMedics Group, Inc.

(TMDX) is pulling ahead at 37. 1% versus 7. 8% for CVS Health Corporation (CVS). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, TMDX leads at 86. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus 2. 6% for CVS. At the gross margin level — before operating expenses — INVA leads at 72. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Innoviva, Inc.

(INVA) trades at 11. 9x forward P/E versus 29. 9x for TransMedics Group, Inc. — 18. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TMDX: 98. 6% to $144. 75.

In this comparison, CVS (3.

1% yield), UNH (2. 4% yield) pay a dividend. TMDX, INVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), 3. 1% yield). TransMedics Group, Inc. (TMDX) carries a higher beta of 1. 59 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CVS: +3. 5%, TMDX: +226. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TMDX is a small-cap high-growth stock; UNH is a large-cap quality compounder stock; INVA is a small-cap high-growth stock; CVS is a mid-cap income-oriented stock. UNH, CVS pay a dividend while TMDX, INVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.